Bingbing Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Bingbing Li has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Changlian Zhu
Henan Key Laboratory of Child Brain Injury and Henan Pediatric Clinical Research Center, Institute of Neuroscience, Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China
3 shared publications - Dan Li
School of psychology Shanghai Normal University Shanghai China
1 shared publication Dizhou Pang
Henan Key Laboratory of Child Brain Injury and Henan Pediatric Clinical Research Center, Third Affiliated Hospital and Institute of Neuroscience, Zhengzhou University, Zhengzhou, China
1 shared publication- Guangen Guo
The Third Affiliated Hospital of Zhengzhou University, Department of Pediatrics, Division of Pulmonology, Zhengzhou, Henan, China
1 shared publication Guiqin Duan
Henan Key Laboratory of Child Brain Injury and Henan Pediatric Clinical Research Center, Third Affiliated Hospital and Institute of Neuroscience, Zhengzhou University, Zhengzhou, China
1 shared publication- Jiajia Duan
The Third Affiliated Hospital of Zhengzhou University, Department of Neonatology, Zhengzhou, Henan, China
1 shared publication
Latest Publications
- Open Access
- 18 November 2025
- Published by Elsevier in Jornal de Pediatria
- Vol. 102 (1) , 101475
Epidemiological and clinical characteristics associated with enterovirus D68 respiratory diseases in Asian children: a systematic review and meta-analysis
- 18 November 2025
- Published by Elsevier in Jornal de Pediatria
- Vol. 102 (1) , 101475
Open AccessEpidemiological and clinical characteristics associated with enterovirus D68 respiratory diseases in Asian children: a systematic review and meta-analysis
- Open Access
- 15 August 2022
- Published by Frontiers Media SA in Frontiers in Molecular Neuroscience
- Vol. 15, 947513
Interrelation between homocysteine metabolism and the development of autism spectrum disorder in children
Evidence is emerging that dysregulation of circulating concentrations of homocysteine, an important intermediate in folate and vitamin B12 metabolism, is associated with autism spectrum disorder (ASD), but comprehensive assessments and correlations with disease characteristics have not been reported. Multivariate ordinal regression and restricted cubic spline (RCS) models were used to estimate independent correlations between serum homocysteine, folate, and vitamin B12 levels and clinical outcomes and severity of children with ASD. After adjusting for confounding factors, serum homocysteine levels were significantly higher in children with ASD than in healthy controls (β: 0.370; 95% CI: 0.299~0.441, p < 0.001). Moreover, homocysteine had a good diagnostic ability for distinguishing children with ASD from healthy subjects (AUC: 0.899, p < 0.001). The RCS model indicated a positive and linear association between serum homocysteine and the risk of ASD. The lowest quartile of folate was positively associated with ASD severity (OR: 4.227, 95% CI: 1.022~17.488, p = 0.041) compared to the highest quartile, and serum folate showed a negative and linear association with ASD severity. In addition, decreased concentrations of folate and vitamin B12 were associated with poor adaptive behavior developmental quotients of the Gesell Developmental Schedules (p < 0.05). Overall, an increased homocysteine level was associated with ASD in a linear manner and is thus a novel diagnostic biomarker for ASD. Decreased concentrations of folate and vitamin B12 were associated with poor clinical profiles of children with ASD. These findings suggest that homocysteine-lowering interventions or folate and vitamin B12 supplementation might be a viable treatment strategy for ASD.
- 15 August 2022
- Published by Frontiers Media SA in Frontiers in Molecular Neuroscience
- Vol. 15, 947513
Open AccessInterrelation between homocysteine metabolism and the development of autism spectrum disorder in children
Evidence is emerging that dysregulation of circulating concentrations of homocysteine, an important intermediate in folate and vitamin B12 metabolism, is associated with autism spectrum disorder (ASD), but comprehensive assessments and correlations with disease characteristics have not been reported. Multivariate ordinal regression and restricted cubic spline (RCS) models were used to estimate independent correlations between serum homocysteine, folate, and vitamin B12 levels and clinical outcomes and severity of children with ASD. After adjusting for confounding factors, serum homocysteine levels were significantly higher in children with ASD than in healthy controls (β: 0.370; 95% CI: 0.299~0.441, p < 0.001). Moreover, homocysteine had a good diagnostic ability for distinguishing children with ASD from healthy subjects (AUC: 0.899, p < 0.001). The RCS model indicated a positive and linear association between serum homocysteine and the risk of ASD. The lowest quartile of folate was positively associated with ASD severity (OR: 4.227, 95% CI: 1.022~17.488, p = 0.041) compared to the highest quartile, and serum folate showed a negative and linear association with ASD severity. In addition, decreased concentrations of folate and vitamin B12 were associated with poor adaptive behavior developmental quotients of the Gesell Developmental Schedules (p < 0.05). Overall, an increased homocysteine level was associated with ASD in a linear manner and is thus a novel diagnostic biomarker for ASD. Decreased concentrations of folate and vitamin B12 were associated with poor clinical profiles of children with ASD. These findings suggest that homocysteine-lowering interventions or folate and vitamin B12 supplementation might be a viable treatment strategy for ASD.
- Open Access
- 5 January 2022
- Published by Frontiers Media SA in Frontiers in Psychology
- Vol. 12, 739585
Electrophysiological Correlates of Shyness Affected by Facial Attractiveness
Previous neurological studies of shyness have focused on the hemispheric asymmetry of alpha spectral power. To the best of our knowledge, few studies have focused on the interaction between different frequencies bands in the brain of shyness. Additionally, shy individuals are even shyer when confronted with a group of people they consider superior to them. This study aimed to reveal the neural basis of shy individuals using the delta-beta correlation. Further, it aimed to investigate the effect of evaluators’ facial attractiveness on the delta-beta correlation of shyness during the speech anticipation phase. We recorded electroencephalogram (EEG) activity of 94 participants during rest and anticipation of the public speaking phase. Moreover, during the speech anticipation phase, participants were presented with high or low facial attractiveness. The results showed that, as predicted, the delta-beta correlation in the frontal region was more robust for high shyness than for low shyness during the speech anticipation phase. However, no significant differences were observed in the delta-beta correlation during the baseline phase. Further exploration found that the delta-beta correlation was more robust for high facial attractiveness than low facial attractiveness in the high shyness group. However, no significant difference was found in the low-shyness group. This study suggests that a stronger delta-beta correlation might be the neural basis for shy individuals. Moreover, high facial attractiveness might enhance the delta-beta correlation of high shyness in anticipation of public speaking.
- 5 January 2022
- Published by Frontiers Media SA in Frontiers in Psychology
- Vol. 12, 739585
Open AccessElectrophysiological Correlates of Shyness Affected by Facial Attractiveness
Previous neurological studies of shyness have focused on the hemispheric asymmetry of alpha spectral power. To the best of our knowledge, few studies have focused on the interaction between different frequencies bands in the brain of shyness. Additionally, shy individuals are even shyer when confronted with a group of people they consider superior to them. This study aimed to reveal the neural basis of shy individuals using the delta-beta correlation. Further, it aimed to investigate the effect of evaluators’ facial attractiveness on the delta-beta correlation of shyness during the speech anticipation phase. We recorded electroencephalogram (EEG) activity of 94 participants during rest and anticipation of the public speaking phase. Moreover, during the speech anticipation phase, participants were presented with high or low facial attractiveness. The results showed that, as predicted, the delta-beta correlation in the frontal region was more robust for high shyness than for low shyness during the speech anticipation phase. However, no significant differences were observed in the delta-beta correlation during the baseline phase. Further exploration found that the delta-beta correlation was more robust for high facial attractiveness than low facial attractiveness in the high shyness group. However, no significant difference was found in the low-shyness group. This study suggests that a stronger delta-beta correlation might be the neural basis for shy individuals. Moreover, high facial attractiveness might enhance the delta-beta correlation of high shyness in anticipation of public speaking.
- 3 December 2019
- Published by Wiley in Journal of Neuroscience Research
- Vol. 98 (5) , 815-825
Umbilical cord blood stem cell therapy in premature brain injury: Opportunities and challenges
Preterm birth and associated brain injury are the primary cause of cerebral palsy and developmental disabilities and are among the most serious global health issues that modern society faces. Current therapy for infants suffering from premature brain injury is still mainly supportive, and there are no effective treatments. Thus there is a pressing need for comparative and translational studies on how to reduce brain injury and to increase regeneration and brain repair in preterm infants. There is strong supporting evidence for the use of umbilical cord blood (UCB)‐derived stem cell therapy for treating preterm brain injury and neurological sequelae. UCB‐derived stem cell therapy is effective in many animal models and has been shown to be feasible in clinical trials. Most of these therapies are still experimental, however. In this review, we focus on recent advances on the efficacy of UCB‐derived stem cell therapy in preterm infants with brain injury, and discuss the potential mechanisms behind their therapeutic effects as well as application strategies for future preclinical and clinical trials.
- 3 December 2019
- Published by Wiley in Journal of Neuroscience Research
- Vol. 98 (5) , 815-825
Umbilical cord blood stem cell therapy in premature brain injury: Opportunities and challenges
Preterm birth and associated brain injury are the primary cause of cerebral palsy and developmental disabilities and are among the most serious global health issues that modern society faces. Current therapy for infants suffering from premature brain injury is still mainly supportive, and there are no effective treatments. Thus there is a pressing need for comparative and translational studies on how to reduce brain injury and to increase regeneration and brain repair in preterm infants. There is strong supporting evidence for the use of umbilical cord blood (UCB)‐derived stem cell therapy for treating preterm brain injury and neurological sequelae. UCB‐derived stem cell therapy is effective in many animal models and has been shown to be feasible in clinical trials. Most of these therapies are still experimental, however. In this review, we focus on recent advances on the efficacy of UCB‐derived stem cell therapy in preterm infants with brain injury, and discuss the potential mechanisms behind their therapeutic effects as well as application strategies for future preclinical and clinical trials.